AI Article Synopsis
- Tocilizumab, an immunosuppressant, shows potential as a treatment for severe COVID-19 cases, similar to how Vitamin D may influence interleukin-6 levels.
- There is a pattern suggesting that seasonal factors affect the severity of illnesses like COVID-19, although data mainly comes from winter months in the Northern Hemisphere.
- Conducting a study comparing Vitamin D levels in blood samples of COVID-19 survivors versus fatalities could support the idea of broad Vitamin D supplementation as a cost-effective alternative to tocilizumab.
Article Abstract
There is anecdotal evidence that tocilizumab, an immunosuppressant drug, may be a potential therapeutic option for patients with severe manifestations of coronavirus disease 2019 (COVID-19). Like tocilizumab, Vitamin D appears to modulate the activity of an interleukin (IL-6), which may explain the seasonal variation in prevalence of influenza. While most cases of COVID-19 have, thus far, occurred in the Northern Hemisphere winter, limiting the ability to assess seasonal variation, there remains substantial variation in the severity of this condition that has yet to be explained. A retrospective comparison of Vitamin D levels in previously obtained blood samples between survivors and confirmed fatalities could establish a rationale for implementation of widespread Vitamin D supplementation. This would be far cheaper and simpler than tocilizumab as a therapeutic option to trial.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177149 | PMC |
| http://dx.doi.org/10.1016/j.mehy.2020.109767 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Quick decisionmaking for acute pulmonary embolism patients].
Ned Tijdschr Geneeskd
December 2024
Leids Universitair Medisch Centrum, Leiden. Afd. Trombose & Hemostase.
Treatment options for patients with severe pulmonary embolism (PE) have increased substantially over the past decade. Although systemic thrombolysis is still the reperfusion therapy of choice for hemodynamically unstable PE patients, several new catheter guided reperfusion therapies have emerged as possibly safer alternatives. These therapies are increasingly implemented in clinical practice even though their efficacy and safety are yet to be proven by clinical outcome studies.
View Article and Find Full Text PDFThe highs and lows of monoamine oxidase as molecular target in cancer: an updated review.
Mol Cell Biochem
December 2024
Department XIII Infectious Diseases-Parasitology, "Victor Babeș" University of Medicine and Pharmacy of Timișoara, Timișoara, Romania.
The global burden of cancer as a major cause of death and invalidity has been constantly increasing in the past decades. Monoamine oxidases (MAO) with two isoforms, MAO-A and MAO-B, are mammalian mitochondrial enzymes responsible for the oxidative deamination of neurotransmitters and amines in the central nervous system and peripheral tissues with the constant generation of hydrogen peroxide as the main deleterious ancillary product. However, given the complexity of cancer biology, MAO involvement in tumorigenesis is multifaceted with different tumors displaying either an increased or decreased MAO profile.
View Article and Find Full Text PDFMachine learning in personalized laryngeal cancer management: insights into clinical characteristics, therapeutic options, and survival predictions.
Eur Arch Otorhinolaryngol
December 2024
King Hussein Cancer Center, Medical Oncology Department, Amman, Jordan.
Purpose: Over the last 40 years, there has been an unusual trend where, even though there are more varied treatments, survival rates have not improved much. Our study used survival analysis and machine learning (ML) to investigate this odd situation and to improve prediction methods for treating non-metastatic LSCC.
Methods: The surveillance, epidemiology and end results (SEER) database provided the data used for this study's analysis.
[Mineralocorticoid receptor antagonists in heart failure with preserved/mildly reduced ejection fraction: from TOPCAT to FINEARTS-HF].
G Ital Cardiol (Rome)
January 2025
U.O.C. Cardiologia 1, Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo.
Mineralocorticoid receptor antagonists (MRAs) represent one of the cornerstones of treatment for heart failure with reduced ejection fraction. Post-hoc data from the TOPCAT trial, conducted in patients with heart failure mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), suggest the possible clinical benefit of MRAs, particularly for slightly reduced ejection fraction values. The advent of non-steroidal MRAs, including finerenone, seems to represent a turning point in the treatment for HFmrEF/HFpEF.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!